A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

A Single-Blind, Randomized, Positive-controlled Study to Compare Monotherapy With an Inhaled Corticosteroid (Mometasone) to Combination Therapy With an Inhaled Corticosteroid + a Long-Acting Bronchodilator (Advair) in Patients With Milder Persistent Asthma

The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma?

The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.

Inclusion Criteria:

• subjects 18 to 65 years of age
• a >2 year history of asthma
• FEV1 > 80% for subjects currently using Advair®.

Exclusion Criteria:

• severe asthma
• current smokers
• pregnant or breast-feeding women
• other chronic significant illnesses